基于信息的组序列设计,用于使用真实数据对医疗产品的市场后安全监测
Zhiwei Zhang1, Carrie Nielson2, Ching-Yi Chuo2
1Biostatistics, Gilead Sciences, Foster City, California, USA.
Pharmaceutical statistics
|April 8, 2024
概括
本研究引入了基于信息的组序列设计,用于市场后药物安全监测. 它解决了样本大小的不确定性,专注于信息积累,以进行可靠的安全评估.
科学领域:
- 药物监督 药物监督 药物监督
- 生物统计学 生物统计学
- 临床试验设计 临床试验设计
背景情况:
- 现实世界医疗保健数据对于医疗产品的市场安全监测至关重要.
- 组序列设计为重复评估安全数据提供了一个严格的框架.
- 产品摄入的不确定性使安全性研究中的样本大小和持续时间的确定变得复杂.
研究的目的:
- 为安全监测研究提出基于信息的组序列设计.
- 为了克服与样本大小和研究设计中的持续时间不确定性相关的挑战.
- 提供一个灵活的框架,适应各种回归模型.
主要方法:
- 一个基于信息的设计,指定一个足够的统计能力的目标信息量.
- 在中间分析中使用差异估计来计算当前信息时间.
- 使用预先指定的alpha支出函数来确定研究停止边界.
- 适用于调整混因子和异质治疗暴露的回归模型.
主要成果:
- 拟议的设计有效地管理了样本大小和研究持续时间的不确定性.
- 它允许基于积累的信息进行严格的安全评估.
- 模拟结果表明,在现实的市场后安全监测场景中表现良好.
结论:
- 基于信息的组序列设计为安全监测研究提供了可靠的解决方案,不确定产品的采用.
- 这种方法提高了药监统计框架的灵活性和严格性.
- 该设计具有适应性,在模拟中表现良好,支持其实际应用.
更多相关视频
15:00Setup of Consumer Wearable Devices for Exposure and Health Monitoring in Population Studies
Published on: February 3, 2023
2.5K
06:32Author Spotlight: Automated Deep Brain Stimulation for Parkinson's Disease - Exploring the Possibilities and Challenges of Home Monitoring
Published on: July 14, 2023
1.3K
相关概念视频
Clinical Trials
6.7K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.7K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
126
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
126
Comparing the Survival Analysis of Two or More Groups
179
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
179
Censoring Survival Data
88
Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different...
88
Assumptions of Survival Analysis
125
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
125
Hazard Ratio
116
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
116
